Dream control: a new behavioral approach to tame narcolepsy nightmares
NCT ID NCT05709873
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests two behavioral therapies—imagery rehearsal therapy (IRT) and targeted dream control (TDC)—to reduce nightmares in adults with narcolepsy. Participants attend therapy sessions, keep a daily sleep log, and complete questionnaires. Some Chicago-area participants also undergo a daytime nap sleep study. The goal is to see if these therapies can lower nightmare frequency and severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imagery rehearsal therapy and targeted dream control
- What this could lead to
- If effective, these therapies could offer a drug-free way to reduce nightmare frequency and severity in people with narcolepsy.
- What could go wrong
- This is a very small early study with only 7 participants, so results may not apply to everyone. The treatments require time and commitment, and not everyone may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do current sleepiness tests work for kids? a new study puts them to the test
- Could a common antibiotic wake up the sleepy brain?
- Zapping the Brain's deep centers: a new approach to narcolepsy?
- New test could sharpen diagnosis of narcolepsy and related sleep disorders
- New pill aims to tame Narcolepsy's sleep attacks and sudden muscle weakness
- New drug TAK-360 tested for Long-Term safety in sleep disorders